AbbVie nabs FDA approval for oral RA therapy JAK inhibitor Rinvoq

17 August 2019
abbvie_us_large

Discovered and developed by AbbVie (NYSE: ABBV), Rinvoq (upadacitinib) marks the second US Food and Drug Administration approval of a targeted immunomodulator (TIM) therapy for the company this year, and provides a back up to its mega blockbuster drug Humira (adalimumab).

Under its priority review system, the FDA approved Rinvoq, a 15mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). Rinvoq is expected to be available in the USA in late August 2019, said AbbVie, whose shares gained 2.3% to $64.43 by close on Friday following the news.

Filling the Humira gap

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology